Uncategorized
Seciera cyclosporine formulation for dry eye improves tear production in phase 2b/3 trial
Seciera significantly improved tear production and reduced ocular surface inflammation in a phase 2b/3 clinical trial, Auven Therapeutics announced in a press release.Seciera (OTX-101) is a nanomicellar formulation of cyclosporine that uses patent-protected technology to enhance penetration into targeted ocular tissues. It is a clear, preservative-free isotonic aqueous solution.